On Jan. 05, Wells David R. divested U.S. $31,500 in shares of ENDRA Life Sciences Inc.. The CFO sold 35,000 shares at a price per share of $0.90. The transaction decreased this specific insider’s holdings to 104,789 shares worth around $88022.76 at present.
Another 11,269 shares were sold by Maloberti Renaud Bertrand, for more than $10,593 in total proceeds. The Chief Commercial Officer dumped the shares at a price of $0.94 and the insider now owns almost 30,311 shares.
Add them to your watchlist before they take off!
Is ENDRA Life Sciences Inc. [NASDAQ:NDRA] a Good Buy Right Now?
It should be noted that NDRA technical indicators for short, intermediate as well as long term progress have placed an overall average of 16% as Buy. The average signal changed from 72% Sell in the last week and compares with 8% Buy in the past month. Data from ENDRA Life Sciences Inc.’s Trend Spotter indicated that the signals were Bearish. The stock current average is 0.87 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.48 million shares while the medium term average advocated for Hold. The average long-term signal stands at Hold and the 100-day average volume stands at 0.32 million shares.
NDRA Price Performance
On Wall Street, ENDRA Life Sciences Inc. [NASDAQ:NDRA] finished Wednesday’s session down -5.54% at $0.84. The stock went up to $0.9403 at the same session while its lowest single day price was $0.8221. In the last five days, it saw a rise of about 18.41%, ENDRA Life Sciences Inc. shares gained by almost 12.09% since the beginning of the year. However, the share price has dropped to as low as -62.64% below its one year high. On 01/06/21, the company shares recorded $0.9403, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $0.7600. The company’s shares have declined by -56.21% in the past year. The 50-day SMA achieved is $0.7822 while the 200-day SMA is $0.8235.
NDRA Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 0.7951 level, and in case of violation of this particular level, it will cause more drop to 0.7495 level. On the upper level, 0.9859 is still the key resistance. The stock may increase to the subsequent resistance at 0.9133. The Relative Strength Index (RSI) pinned on the 14-day chart is 55.83, implying a neutral technical stance while the MACD stands at 0.0791, meaning price will decrease in the next trading period. Percent R indicator moved to 41.97%, implying low price movement. Stochastic %K at 59.29% suggest holding the stock.
What is the short interest in ENDRA Life Sciences Inc.?
Short interest in the ENDRA Life Sciences Inc. stock has plunged, decreasing by 14400.0 shares to total 0.54 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.52 million, data from Yahoo Finance shows. The increase of 2.68% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 2.29% of the overall float for the stock.
ENDRA Life Sciences Inc.’s Biggest Shareholders: Who Owns ENDRA Life Sciences Inc. [NDRA]?
Filings by ICM Asset Management, Inc. showed that the firm now holds a total of 409,861 shares or roughly 1.63% of the outstanding NDRA shares. This means their shares have increased by 8,000 from the 409,861 the investor reportedly held in its prior 13-F filing. With the conclusion of the purchase, KJ Harrison & Partners, Inc. updated stake is worth $141,623. Details in the latest 13F filings reveal that The Vanguard Group, Inc. disposed off their 0.00% stake valued at $80,376 while Geode Capital Management LLC cut theirs at $52,485. During the last quarter, The Vanguard Group, Inc. liquidated 0 of its shares in ENDRA Life Sciences Inc.. The Citadel Advisors LLC’s holdings currently number 44,941 shares at $37750.44. According to the firm’s last 13F report, Virtu Financial BD LLC shares in the company at filing stood at 41,738 shares, roughly $34,267.
What are analyst thoughts on ENDRA Life Sciences Inc.?
Looking forward to the ENDRA Life Sciences Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for ENDRA Life Sciences Inc. stock at $6.00 within the next 12 months, which represents almost 86.0 per cent growth from its previous closing price of $0.84. The highest analysts’ target for ENDRA Life Sciences Inc. stock projections is $6.00 and the lowest one is $3.50. Still, 3 analysts sharing their consensus rating for NDRA stock in 2021 agree that it is a Buy.